Search Results

BACK FACT-NP Scoring Downloads Download DOC

FAPSI Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 8 Item Version For patients with Prostate cancer; A FACT-Prostate Symptom Index (a subset of FACT-P containing 8 items) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FAPSI measure: MEASURE NAME: Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 8 Item Version (FAPSI) VERSION: 4 NUMBER OF ITEMS: 8 PATIENT POPULATION: Prostate cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Prostate cancer subscale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. SAS/SPSS algorithms available. RELATED MEASURES: FACT-P , NFPSI-17 , FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FAPSI can be obtained by registering for permission. Users are not permitted to translate the FAPSI without permission from FACIT.org. Permission from FACIT.org to translate the FAPSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network ; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Yount, S., Cella, D., Banik, D., Ashraf, T., & Shevrin, D. (2003). Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health and quality of life outcomes 1 69. doi:10.1186/1477-7525-1-69. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-P Functional Assessment of Cancer Therapy – Prostate LEARN MORE NFPSI-17 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

BACK FAIT-F Scoring Downloads Download DOC

BACK FACT-EGFRI-18 Scoring Downloads Download DOC

BACK FACIT-Fatigue Scoring Downloads Download DOC

BACK FCSI Scoring Downloads Download DOC

BACK FACIT-BTCSQ English Downloads Download PDF - Baseline Download DOC - Baseline Download PDF - On Therapy Download DOC - On Therapy

CRRS Caregiver Roles and Responsibilities Scale For caregivers of cancer patients LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The caregiver roles and responsibilities scale (CRRS) was developed to facilitate formal assessment of broad life impacts for informal (i.e. unpaid) caregivers to people with cancer. MEASURE NAME: Caregiver Roles and Responsibilities Scale (CRRS) VERSION: 1 NUMBER OF ITEMS: 43 to 51 PATIENT POPULATION: Caregivers of cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Support and Impact, Lifestyle, Emotional Health and Well-being, Self-care, Financial Well-being, Jobs and Career TIME FOR COMPLETION: 15-20 minutes SCORING: Manual scoring template RELATED MEASURES: PRRS , FACT-G Caregiver , FACT-G7 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the CRRS can be obtained when licensing the measure. Users are not permitted to translate the CRRS without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the CRRS. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Shilling V, Starkings R, Jenkins V, Cella D, Fallowfield L. Development and validation of the caregiver roles and responsibilities scale in cancer caregivers. Qual Life Res . 2019 Jun;28(6):1655-1668. doi: 10.1007/s11136-019-02154-4. Epub 2019 Mar 18. PMID: 30887387; PMCID: PMC6522459. Shilling V, Matthews L, Jenkins V, Fallowfield L. Patient-reported outcome measures for cancer caregivers: a systematic review. Qual Life Res . 2016 Aug;25(8):1859-76. doi: 10.1007/s11136-016-1239-0. Epub 2016 Feb 12. PMID: 26872911; PMCID: PMC4945691. LICENSE THIS MEASURE Related Measures Related Measures PRRS Patient Roles and Responsibilities Scale LEARN MORE FACT-G Caregiver Functional Assessment of Cancer Therapy – General – Caregiver Version LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE

BACK FACT-GOG-NTX-13 Languages Chinese - Simplified Chinese - Traditional Czech Danish Dutch English Finnish French German Greek Gujarati Hindi Hungarian Italian Japanese Korean Marathi Portuguese Russian Sesotho Setswana Spanish Swedish Turkish

BACK NFBlSI-18 Languages Afrikaans Arabic Bengali Bulgarian Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Slovene Spanish Swedish Tamil Telugu Turkish Xhosa Zulu

FACT-AntiA Functional Assessment of Cancer Therapy – AntiAngiogenesis For patients receiving Anti-Angiogenesis therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-AntiA measure: MEASURE NAME: Functional Assessment of Cancer Therapy – AntiAngiogenesis (FACT-AntiA) VERSION: 4 NUMBER OF ITEMS: 50 PATIENT POPULATION: Patient population: Cancer patients 18 years and older receiving anti-angiogenesis treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, AntiAngiogenesis Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT/GOG-NTX , FACT-BRM , FACT-BMT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-AntiA can be obtained by registering for permission. Users are not permitted to translate the FACT-AntiA without permission from FACIT.org. Permission from FACIT.org to translate the FACT-AntiA may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Kaiser K., Beaumont J.L., Webster K., Yount S.E., Wagner L.I., Kuzel T.M., Cella D. Development and validation of the Functional Assessment of Cancer Therapy – Antiangiogenesis subscale. Cancer Med 2015; May 4(5): 690-698. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT-BRM Functional Assessment of Cancer Therapy - Biologic Response Modifiers LEARN MORE FACT-BMT Functional Assessment of Cancer Therapy - Bone Marrow Transplantation LEARN MORE

FACT-P Functional Assessment of Cancer Therapy – Prostate For patients with Prostate cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-P measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Prostate (FACT-P) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Prostate cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Prostate Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FPSI , NFPSI-17 , FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-P can be obtained by registering for permission. Users are not permitted to translate the FACT-P without permission from FACIT.org. Permission from FACIT.org to translate the FACT-P may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Beaumont, J., Butt, Z., Li, R., & Cella, D. Meaningful Differences and Validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. Cancer 2019; 125(11): 1877-1885. doi: 10.1002/cncr.31973. Beer, T., Miller, K., Tombal, B., Cella, D., DePhung, Holmstrom, S., Ivanescu, C., Skaltsa, K., & Naidoo, S. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. European Journal of Cancer 2017; 87: 21-29. doi: 10.1016/j.ejca.2017.09.035. Cella, D., Petrylak, D., Fishman, M., Teigland, C., Young, J., & Mulani, P. Role of quality of life in men with metastatic hormone-refactory prostate cancer: How does Astrsentan influence quality of life? European Urology 2006; 49: 781-789. doi: 10.1016/j.eururo.2005.12.05. Cella, D., Nichol, M., Eton, D., Nelson, J., & Mulani, P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health 2009; 12(1): 124-129. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K.J. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument. Urology 1997; 50(6): 920-928. Orakwe, D., Tijani, K., Jeje, E., Ogunjimi, M., Rufus, W., & Alab, T. Bilateral Subcapsular Orchiectomy versus Bilateral Total Orchiectomy: Comparison of the Quality of Life Post‑Orchiectomy. Nigerian Postgraduate Medical Journal 2018; 25(1): 43-47. doi: 10.4103/npmj.npmj_169_17. Parker, C., Nilsson, s., Heinrich, D., Helle, S., O’Sullivan, J., Fosså, S., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D., Hoskin, P., Bottomley, D., James, N., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall’Oglio, M., Franzén, L., Coleman, R., Vogelzang, N., O’Bryan-Tear, C., Staudacher, K.., Garcia-Vargas, J., Shan, M., Bruland, Ø.., & Sartor, O. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. The New England Journal of Medicine 2013; 369(3): 213-223. doi: 10.1056/NEJMoa121375. Saad, F., Cella, D., Basch, E., Hadaschik, B., Mainwaring, P., Oudard, S., Graff, J., McQuarrie, K., Li, S., Hudgens, S. Lawson, J., Lopez-Gitlitz, A., Yu, M., Smith, M., & Small, E. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2018; 19(10):1404-1416. doi: 10.1016/ S1470-2045(18)30567-9. Sullivan, P. Nelson, J., Mulani, P., & Slee, D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research 2006; 15: 1297–1306. doi: 10.1007/s11136-006-0003-2. Vashistha, V., Singh, B., Kaur, S., Prokop, L., & Kaushik, D. The Effects of Exercise on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer: Systematic Review and Meta-analyses. European Urology Focus 2016; 2(3): 284-295. doi: 10.1016/j.euf.2016.02.011. Victorson, D., Beaumont, J, Rosenbloom, S., Shevrin, D, & Cella, D. Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P symptom index. Psycho-Oncology 2011; 20(9): 977-983. doi: 10.1002/pon.1817. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FPSI Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 7 Item Version LEARN MORE NFPSI-17 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE